Bullish Case: Signatera's MRD ramp (Q2 revenue +38%, ASP ~$1,275, FY guide $2.85-2.91B) keeps compounding; the Angiex AGX101 partnership extends Signatera into ADC response monitoring. Calls traded 90% more than puts, bullish risk exceeds bearish by 19% across tenors, and Helium's density peaks near $350-360 with a fat upside wing toward $440+, consistent with contango and post-earnings IV decay.

Bearish Case: NTRA is up ~50% in 90 days and 13% in a week at 5.8x book—valuation and momentum-stretch risk are real. The market density peaks below spot (~$360) with a heavy left tail to $300, put-wing IV remains rich (310-320P at 52-60 IV), and November IV (~52-55) exceeds October, pricing event risk. A reimbursement, margin, or guidance wobble could reprice fast from this altitude.

Potential Outcomes:

• 35% — Consolidation $360-410: post-run digestion, IV mean-reverts as Oct/Nov catalysts pass.
• 25% — Beat-and-continue: MRD/ASP momentum or new data drives $420-460 by year-end.
• 20% — Profit-taking pullback to $330-360 on valuation, matching market-density peak.
• 12% — Guidance/reimbursement disappointment: -15-20% toward $310-330.
• 8% — Tail event (payer/regulatory shock or vol spike): >25% move, put-wing IV >60% spikes.

September 23, 2026